The objective was to design in gerbils a model of reversible decrease in cochlear blood flow (CBF) and analyze its influence on cochlear function. In Mongolian gerbils injected with ferromagnetic microbeads, a magnet placed near the porus acusticus allowed CBF to be manipulated. The cochlear microphonic potential (CM) from the basal cochlea was monitored by a round-window electrode. In 13 of the 20 successfully injected gerbils, stable CBF reduction was obtained for 11.5 min on average. The CM was affected only when CBF fell to less than 60% of its baseline, yet remained >40% of its initial level in about 2/3 of such cases. After CBF restoration, CM recovery was fast and usually complete. Reduced CM came with a 35- to 45-dB threshold elevation of neural responses determined by compound action potentials. This method allowing reversible changes of CBF confirms the robustness of cochlear function to decreased CBF. It can be used to study whether a hypovascularized cochlea is abnormally sensitive to stress.

Keywords:
Cochlear blood flow, Cochlear microphonic potential, Cerebellopontine angle
1.
Asai Y, Umemura K, Kohno Y, Uematsu T, Nakashima M: An animal model for hearing disturbance due to inner ear ischemia: photochemically induced thrombotic occlusion of the rat anterior inferior cerebellar artery. Eur Arch Otorhinolaryngol 1993;250:292-296.
2.
Giebel W, Strömer H, Arold R: Experimentelle Untersuchungen zur Ischämie der Cochlea. 1. Methodik. Laryngo-Rhino-Otologie 1992;71:161-167.
3.
Mom T, Avan P, Bonfils P, Gilain L: A model of cochlear function assessment during reversible ischemia in the Mongolian gerbil. Brain Res Prot 1999a;4:249-257.
4.
Mom T, Avan P, Romand R, Gilain L: Monitoring of functional changes after transient ischemia in gerbil cochlea. Brain Res 1997;751:20-30.
5.
Mom T, Bonfils P, Gilain L, Avan P: Vulnerability of the gerbil cochlea to sound exposure during reversible ischemia. Hear Res 1999b;136:65-74.
6.
Mom T, Montalban A, Khalil T, Gabrillargues J, Chazal J, Gilain L, Avan P: Vasospasm of labyrinthine artery in cerebellopontine angle surgery: evidence brought by distortion-product otoacoustic emissions. Eur Arch Otorhinolaryngol 2014;271:2627-2635.
7.
Morawski K, Namyslowski G, Lisowska G, Bazowski P, Kwiek S, Telischi FF: Intraoperative monitoring of cochlear function using distortion product otoacoustic emissions (DPOAEs) in patients with cerebellopontine angle tumors. Otol Neurotol 2004;25:818-825.
8.
Patuzzi RB, Yates GK, Johnstone BM: The origin of the low-frequency microphonic in the first cochlear turn of guinea-pig. Hear Res 1989;39:177-188.
9.
Perlman HB, Kimura M, Fernandez C: Experiments on temporary obstructions of the internal auditory artery. Laryngoscope 1959;69:591-613.
10.
Ren TY, Brown NJ, Zhang MS, Nuttall AL, Miller JM: A reversible ischemia model in gerbil cochlea. Hear Res 1995;92:30-37.
11.
Scheibe F, Haupt H, Baumgärtl H: Effects of experimental cochlear thrombosis on oxygenation and auditory function of the inner ear. Eur Arch Otorhinolaryngol 1997;254:91-94.
12.
Telischi FF, Widick MP, Lonsbury-Martin BL, McCoy MJ: Monitoring cochlear function intraoperatively using distortion product otoacoustic emissions. Am J Otol 1995;16:597-608.
© 2017 S. Karger AG, Basel
2017
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.